HRP20090589T1 - Izokinolinski derivati kao inhibitori ro-kinaze - Google Patents
Izokinolinski derivati kao inhibitori ro-kinaze Download PDFInfo
- Publication number
- HRP20090589T1 HRP20090589T1 HR20090589T HRP20090589T HRP20090589T1 HR P20090589 T1 HRP20090589 T1 HR P20090589T1 HR 20090589 T HR20090589 T HR 20090589T HR P20090589 T HRP20090589 T HR P20090589T HR P20090589 T1 HRP20090589 T1 HR P20090589T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkylene
- aryl
- halogen
- compound according
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
- 102000000568 rho-Associated Kinases Human genes 0.000 title 1
- 108010041788 rho-Associated Kinases Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 74
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 229910052736 halogen Inorganic materials 0.000 claims abstract 37
- 150000002367 halogens Chemical class 0.000 claims abstract 37
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 27
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 14
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000003925 brain function Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Spoj formule (I) gdjeR1 jeH, (C1-C6)alkil, R', NH-(C1-C6)alkil, NHR', iliN[(Cl-C6)alkil]2;R2 je vodik, halogen ili (C1-C6)alkil; R3 jeH, halogen, (C1-C6)alkil, (C1-C6)alkilen-R', OH, O-R''NH2,NHR'', NR''R'' iliNH-C(O)-R'', R4 jeH, halogen, hidroksi, CN, (C1-C6)alkil, R', (C1-C6)alkilen-R'; R5 jeH, halogen, CN, NO2, (C1-C6)alkil, (C2-C6)alkenil, R' (C1-C6)alkilen-(C6-C10)aril, (C2-C6)alkenilen-(C6-C10)aril, (C1-C6)alkilen-(C5-C10)heterociklil, CH(OH)-(C1-C8)alkil, NH2,NH-R', NH-SO2H, NH-SO2-(C1-C6)alkil, NH-SO2-R', NH-C(O)-(C1-C6)alkil, NH-C(O)-R', C(O)N[(C1-C6)alkil]2,C(O)OH, iliC(O)O-(C1-C6)alkil; R6 jeH, R', (C1-C8)alkil, (C1-C6)alkil-R', (C1-C6)alkilen-O-(C1-C6)alkil, (C1-C6)alkilen-O-R', (C1-C6)alkilen-CH[R']2, (C1-C6)alkilen-C(O)-R', (C1-C6)alkilen-C(O)NH2, (C1-C6)alkilen-C(O)N-R', ili (C1-C5)alkilen-C(O)N[R']2;R7 jeH, halogen, CN, NO2, (C1-C6)alkil, (C2-C6)alkenR' (C2-C6)alkenilen-(C6-C10)aril, (C1-C6)alkilen-R', CH(OH)-(C1-C6)alkil, NH2,NH-R', NH-SO2H, NH-SO2-(C1-C6)alkil, NH-SO2-R', SO2-NH2,SO2-NHR', NH-C(O)-(C1-C6)alkil, NH-C(O)-R', C(O)N[(C1-C6)alkil]2,C(O)OH, iliC(O)O-(C1-C6)alkil; R8 je H, halogen ili (C1-C6)alkil; n je 1, 2, 3 ili 4; iL je O ili O-(C1-C6)alkilen; gdjeR' je (C3-C8)cikloalkil, (C5-C10)heterociklil, (C6-C10)aril; iR'' je (C3-C8)cikloalkil, (C5-C10)heterociklil, (C6-C10)aril, (C1-C6)alkil, (C1-C6)alkilen-R', (C1-C6)alkilen-O-(C1-C6)alkil, (C1-C6)alkilen-O-R', ili (C1-C6)alkilen-NRxRy; igdje Rx i Ry su međusobno neovisno (C1-C6)alkil, (C5-C10)heterociklil, (C6-C10)aril, (C1-C4)alkilen-(C5-C10)heterociklil, (C1-C4)alkilen-(C6-C10)aril, (C1-C4)alkilen-NH(C1-C6)alkil, (C1-C4)alkilen-N[(C1-C6)alkil]2, (C1-C4)alkilen-N[(C6-C10)alkil]2, ili (C1-C4)alkilen-N[(C5-C10)heterociklil]2; igdje u ostacima R4, R5, R7 i R8 jedan alkilni ili alkilenski atom vodika može izborno biti supstituiran s OH, F, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 ili CON(CH3)2;i njegove farmaceutski prihvatljive soli. Patent sadrži još 35 patentnih zahtjeva.
Claims (36)
1. Spoj formule (I)
[image]
gdje
R1 je
H,
(C1-C6)alkil,
R',
NH-(C1-C6)alkil,
NHR', ili
N[(Cl-C6)alkil]2;
R2 je vodik, halogen ili (C1-C6)alkil;
R3 je
H,
halogen,
(C1-C6)alkil,
(C1-C6)alkilen-R',
OH,
O-R''
NH2,
NHR'',
NR''R'' ili
NH-C(O)-R'',
R4 je
H,
halogen,
hidroksi,
CN,
(C1-C6)alkil,
R',
(C1-C6)alkilen-R';
R5 je
H,
halogen,
CN,
NO2,
(C1-C6)alkil,
(C2-C6)alkenil,
R'
(C1-C6)alkilen-(C6-C10)aril,
(C2-C6)alkenilen-(C6-C10)aril,
(C1-C6)alkilen-(C5-C10)heterociklil,
CH(OH)-(C1-C8)alkil,
NH2,
NH-R',
NH-SO2H,
NH-SO2-(C1-C6)alkil,
NH-SO2-R',
NH-C(O)-(C1-C6)alkil,
NH-C(O)-R',
C(O)N[(C1-C6)alkil]2,
C(O)OH, ili
C(O)O-(C1-C6)alkil;
R6 je
H,
R',
(C1-C8)alkil,
(C1-C6)alkil-R',
(C1-C6)alkilen-O-(C1-C6)alkil,
(C1-C6)alkilen-O-R',
(C1-C6)alkilen-CH[R']2,
(C1-C6)alkilen-C(O)-R',
(C1-C6)alkilen-C(O)NH2,
(C1-C6)alkilen-C(O)N-R', ili
(C1-C5)alkilen-C(O)N[R']2;
R7 je
H,
halogen,
CN,
NO2,
(C1-C6)alkil,
(C2-C6)alken
R'
(C2-C6)alkenilen-(C6-C10)aril,
(C1-C6)alkilen-R',
CH(OH)-(C1-C6)alkil,
NH2,
NH-R',
NH-SO2H,
NH-SO2-(C1-C6)alkil,
NH-SO2-R',
SO2-NH2,
SO2-NHR',
NH-C(O)-(C1-C6)alkil,
NH-C(O)-R',
C(O)N[(C1-C6)alkil]2,
C(O)OH, ili
C(O)O-(C1-C6)alkil;
R8 je H, halogen ili (C1-C6)alkil;
n je 1, 2, 3 ili 4; i
L je O ili O-(C1-C6)alkilen;
gdje
R' je
(C3-C8)cikloalkil,
(C5-C10)heterociklil,
(C6-C10)aril; i
R'' je
(C3-C8)cikloalkil,
(C5-C10)heterociklil,
(C6-C10)aril,
(C1-C6)alkil,
(C1-C6)alkilen-R',
(C1-C6)alkilen-O-(C1-C6)alkil,
(C1-C6)alkilen-O-R', ili
(C1-C6)alkilen-NRxRy; i
gdje Rx i Ry su međusobno neovisno
(C1-C6)alkil,
(C5-C10)heterociklil,
(C6-C10)aril,
(C1-C4)alkilen-(C5-C10)heterociklil,
(C1-C4)alkilen-(C6-C10)aril,
(C1-C4)alkilen-NH(C1-C6)alkil,
(C1-C4)alkilen-N[(C1-C6)alkil]2,
(C1-C4)alkilen-N[(C6-C10)alkil]2, ili
(C1-C4)alkilen-N[(C5-C10)heterociklil]2; i
gdje u ostacima R4, R5, R7 i R8 jedan alkilni ili alkilenski atom vodika može izborno biti supstituiran s OH, F, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 ili CON(CH3)2;
i njegove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, gdje R1 je H, (C1-C6)alkil, (C6-C10)aril, NH-(C1-C6)alkil, NH-(C6-C10)aril ili N[(C1-C6)alkil]2.
3. Spoj u skladu s jednim od patentnih zahtjeva 1 ili 2, gdje R1 je H, (C1-C4)alkil, NH-(C1-C4)akil, N[(C1-C4) alkil]2 ili NH-fenil.
4. Spoj u skladu s jednim od patentnih zahtjeva 1 do 3, gdje R1 je H, (C1-C2)alkil ili NH-(C1-C2)alkil.
5. Spoj u skladu s jednim od patentnih zahtjeva 1 do 4, gdje R1 je H.
6. Spoj u skladu s jednim od patentnih zahtjeva 1 do 5, gdje R3 je H, halogen, (C1-C4)alkilen-R', O-R'' ili NHR'', gdje R' i R'' su definirani kao u patentnom zahtjevu 1.
7. Spoj u skladu s jednim od patentnih zahtjeva 1 do 6, gdje R3 je H ili NHR''.
8. Spoj u skladu s jednim od patentnih zahtjeva 1 do 7, gdje R3 je H; NH-(C5-C6)heterociklil, po mogućnosti NH-(C5-C6) heteroaril, koji sadrži jedan ili više N atoma; ili NH-fenil.
9. Spoj u skladu s jednim od patentnih zahtjeva 1 do 8, gdje R8 je H, halogen ili (C1-C4)alkil.
10. Spoj u skladu s jednim od patentnih zahtjeva 1 do 9, gdje R8 je H, Cl, F, metil ili etil.
11. Spoj u skladu s jednim od patentnih zahtjeva 1 do 10, gdje R4 je H, halogen ili (C1-C6)alkil.
12. Spoj u skladu s jednim od patentnih zahtjeva 1 do 11, gdje R4 je H, halogen ili (C1-C4)alkil.
13. Spoj u skladu s jednim od patentnih zahtjeva 1 do 12, gdje R4 je H.
14. Spoj u skladu s jednim od patentnih zahtjeva 1 do 13, gdje R5 je H, halogen, CN, (C1-C6)alkil, R', NH-(C8-C10)aril, (C1-C6)alkilen-(C6-C10)aril ili (C1-C6)alkilen-(C5-C10)heterociklil,
15. Spoj u skladu s jednim od patentnih zahtjeva 1 do 14, gdje R5 je H, halogen, (C1-C6)alkil, R', NH-(C6-C10) aril, (C1-C6)alkilen-(C5-C10)aril ili (C1-C6)alkilen-(C5-C10)heterociklil.
16. Spoj u skladu s jednim od patentnih zahtjeva 1 do 15, gdje R5 je H, halogen, (C1-C6)alkil, (C6-C10)aril, NH-(C6-C10)aril, (C1-C2)alkil-(C6-C10)aril ili (C5-C10)heteroaril.
17. Spoj u skladu s jednim od patentnih zahtjeva 1 do 16, gdje R7 je H, halogen, CN, (C1-C6)alkil, (C2-C6) alkenil, R' ili (C1-C6)alkilen-(C3-C8)cikloalkil.
18. Spoj u skladu s jednim od patentnih zahtjeva 1 do 17, gdje R7 je H, halogen, CN, (C1-C4)alkil, (C1-C4) alkenil, fenil, ciklopropil ili (C5-C6)heteroaril.
19. Spoj u skladu s jednim od patentnih zahtjeva 1 do 18, gdje R7 je H, fluor, klor, brom, metil, etil, fenil, nitril, ciklopropil, tienil ili vinil.
20. Spoj u skladu s jednim od patentnih zahtjeva 1 do 19, gdje n je 1, 2 ili 3.
21. Spoj u skladu s jednim od patentnih zahtjeva 1 do 20, gdje n je 1.
22. Spoj u skladu s jednim od patentnih zahtjeva 1 do 21, gdje R2 je H, halogen ili (C1-C4)alkil.
23. Spoj u skladu s jednim od patentnih zahtjeva 1 do 22, gdje R2 je H ili (C1-C4)alkil.
24. Spoj u skladu s jednim od patentnih zahtjeva 1 do 23, gdje R2 je H, (C1-C2)alkil.
25. Spoj u skladu s jednim od patentnih zahtjeva 1 do 24, gdje R6 je H, (C1-C6)alkil, R', (C1-C4)alkilen-(C3-C8) cikloalkil, (C1-C4)alkilen-(C5-C10)heterociklil, (C1-C4)alkilen-C(O)-(C5-C10)heterociklil, (C1-C4)alkilen-C(O)-(C6-C10)aril ili (C1-C6)alkilen-(C6-C10)aril.
26. Spoj u skladu s jednim od patentnih zahtjeva 1 do 25, gdje R6 je H, (C1-C6)alkil, (C5-C10)heterociklil, (C1-C4) alkilen-(C5-C10)heterociklil ili (C1-C6)alkilen-(C6-C10)aril.
27. Spoj u skladu s jednim od patentnih zahtjeva 1 do 26, gdje L je vezan na položaju 3 ili na položaju 4 u piperidinskom prstenu.
28. Spoj u skladu s jednim od patentnih zahtjeva 1 do 27, gdje L je vezan na položaju 4 u piperidinskom prstenu.
29. Spoj u skladu s jednim od patentnih zahtjeva 1 do 28, gdje L je O-metilen, O-etilen ili po mogućnosti O.
30. Spoj u skladu s patentnim zahtjevom 1, gdje
R1 je H, (C1-C6)alkil, (C6-C10)aril, NH-(C1-C6)alkil, NH-(C6-C10)aril, ili N[(C1-C6)alkil]2;
R2 je vodik, halogen, ili (C1-C6)alkil;
R3 je H, halogen, (C1-C4)alkilen-R', O-R'' ili NHR'', gdje R' i R'' su definirani kao u patentnom zahtjevu 1;
R4 je H, halogen ili (C1-C6)alkil;
R5 je H, (C1-C6)alkil, halogen, CN, (C6-C10)aril, NH-(C6-C10)aril, (C1-C6)alkilen-(C6-C10)aril, (C5-C10) heterociklil ili (C1-C6)alkilen-(C5-C10)heterociklil;
R6 je H, (C1-C6)alkil, R', (C1-C4)alkilen-(C5-C10)heterociklil, (C1-C6)alkilen-C(O)-(C6-C10)aril, (C1-C4) alkilen-C(O)-(C5-C10)heterociklil, ili (C1-C6)alkilen-(C6-C10)aril;
R7 je H, halogen, CN, (C1-C6)alkil, (C2-C6)alkenil ili R';
R8 je H, halogen ili (C1-C6)alkil;
n je 1, 2 ili 3; i
L je O, O-metilen ili O-etilen.
31. Spoj u skladu s patentnim zahtjevom 1, gdje
R1 je H, (C1-C6)alkil, (C6-C10)aril, NH-(C1-C6)alkil, NH-(C6-C10)aril, ili N[(C1-C6)alkil]2;
R2 je H ili (C1-C4)alkil;
R3 je H, halogen ili NHR'', gdje R'' je definiran kao gore;
R4 je H, halogen ili (C1-C4)alkil;
R5 je H, (C1-C6)alkil, halogen, (C6-C10)aril, NH-(C6-C10)aril, (C1-C6)alkilen-(C6-C10)aril ili (C5-C10) heterociklil;
R6 je H, (C1-C6)alkil, R', (C1-C4)alkilen-(C5-C10)heterociklil ili (C1-C6)alkilen-(C6-C10)aril;
R7 je H, halogen, CN, (C1-C6)alkil, (C2-C6)alkenil ili R';
R8 je H, halogen ili (C1-C6)alkil;
n je 1, 2 ili 3; i
L je O.
32. Spoj u skladu s patentnim zahtjevom 1, gdje
R1 je H, (C1-C4)alkil, NH-(C1-C4)alkil, N[(C1-C4)alkil]2 ili NH-fenil;
R2 je H, (C1-C4)alkil;
R3 je H, NH-(C5-C6)heteroaril ili NH-fenil;
R4 je H, halogen ili (C1-C4)alkil;
R5 je H, (C1-C4)alkil, halogen, (C6-C10)aril, NH-(C6-C10)aril, (C1-C2)alkil-(C6-C10)aril ili (C5-C10)heteroaril;
R6 je H, (C1-C6)alkil, (C5-C10)heterociklil, (C1-C4)alkilen-(C5-C10)heterociklil, (C6-C10)aril ili (C1-C6)alkilen-(C6-C10)aril;
R7 je H, halogen, CN, (C1-C4)alkil, (C1-C4)alkenil, fenil, ciklopropil, (C5-C6)heteroaril;
R8 je H, halogen ili (C1-C4)alkil;
n je 1; i
L je O.
33. Spoj formule (I), u skladu s patentnim zahtjevom 1, kojeg se bira iz skupine
[image]
[image]
[image]
i njihove farmaceutski prihvatljive soli.
34. Upotreba najmanje jednog spoja formule (I) i/ili njegove fiziološki prihvatljive soli u skladu s jednim od patentnih zahtjeva 1 do 33, u proizvodnji medikamenta.
35. Upotreba najmanje jednog spoja formule (I) i/ili njegove fiziološki prihvatljive soli u skladu s jednim od patentnih zahtjeva 1 do 33, u proizvodnji medikamenta za liječenje i/ili sprječavanje hipertenzije, plućne hipertenzije, očne hipertenzije, poremećaja perifernog krvotoka, angine pektoris, cerebralnog vazospazma, astme, prijevremenog porođaja, hiperagregabilnosti trombocita, periferne okluzivne arterijske bolesti (PAOD), kronične opstruktivne plućne bolesti (COPD), razvoja raka, erektilne disfunkcije, arterioskleroze, ishemičnog zatajenja organa (krajnjeg oštećenja organa), fibroidnih pluća, fibroidne jetre, zatajenja jetre, fibroidnog bubrega, bubrežene glomeruloskleroze, zatajenja bubrega, hipertrofije organa, hipertrofije prostate, komplikacija dijabetesa, restenoze krvnih žila, ateroskleroze, raka, hipertrofije srca, zatajenja srca kod ishemičnih bolesti; upale; autoimunih bolesti; AIDS-a, osteopatije, poput osteoporoze, poremećaja moždanih funkcija, bakterijske infekcije probavnog sustava, sepse, sindroma dišnog distresa kod odraslih, retinopatije, glaukoma ili Alzheimerove bolesti.
36. Medikament, koji sadrži djelotvornu količinu najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 33, i/ili njegove farmakološki prihvatljive soli, fiziološki podnošljive pomoćne tvari i podloge, te, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05013868 | 2005-06-28 | ||
| PCT/EP2006/005648 WO2007000240A1 (en) | 2005-06-28 | 2006-06-13 | Isoquinoline derivatives as inhibitors of rho-kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090589T1 true HRP20090589T1 (hr) | 2009-12-31 |
Family
ID=35395794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090589T HRP20090589T1 (hr) | 2005-06-28 | 2009-11-03 | Izokinolinski derivati kao inhibitori ro-kinaze |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8501736B2 (hr) |
| EP (1) | EP1899322B1 (hr) |
| JP (1) | JP5097701B2 (hr) |
| KR (1) | KR101327780B1 (hr) |
| CN (1) | CN101213187B (hr) |
| AR (1) | AR054518A1 (hr) |
| AT (1) | ATE441641T1 (hr) |
| AU (1) | AU2006264043B2 (hr) |
| BR (1) | BRPI0613597A2 (hr) |
| CA (1) | CA2611295C (hr) |
| CY (1) | CY1110108T1 (hr) |
| DE (1) | DE602006008945D1 (hr) |
| DK (1) | DK1899322T3 (hr) |
| DO (1) | DOP2006000149A (hr) |
| ES (1) | ES2331853T3 (hr) |
| GT (1) | GT200600273A (hr) |
| HK (1) | HK1122276A1 (hr) |
| HR (1) | HRP20090589T1 (hr) |
| IL (1) | IL188380A (hr) |
| MA (1) | MA29535B1 (hr) |
| MX (1) | MX2008000017A (hr) |
| MY (1) | MY146037A (hr) |
| NZ (1) | NZ565040A (hr) |
| PA (1) | PA8683501A1 (hr) |
| PE (1) | PE20070141A1 (hr) |
| PL (1) | PL1899322T3 (hr) |
| PT (1) | PT1899322E (hr) |
| RS (1) | RS51139B (hr) |
| RU (1) | RU2443688C2 (hr) |
| SI (1) | SI1899322T1 (hr) |
| TW (1) | TWI372756B (hr) |
| UY (1) | UY29641A1 (hr) |
| WO (1) | WO2007000240A1 (hr) |
| ZA (1) | ZA200710001B (hr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| MX2009005825A (es) * | 2006-12-27 | 2009-06-16 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. |
| BRPI0721180A2 (pt) * | 2006-12-27 | 2014-03-18 | Sanofi Aventis | Derivados de isoquinolina substituídos com cicloalquilamina |
| CA2673919C (en) * | 2006-12-27 | 2015-06-23 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives |
| MY148902A (en) * | 2006-12-27 | 2013-06-14 | Sanofi Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009156100A1 (en) * | 2008-06-24 | 2009-12-30 | Sanofi-Aventis | Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
| WO2009156092A2 (en) * | 2008-06-24 | 2009-12-30 | Sanofi-Aventis | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives |
| WO2009156099A1 (en) * | 2008-06-24 | 2009-12-30 | Sanofi-Aventis | 6-substituted isoquinolines and isoquinolinones |
| GB0812969D0 (en) * | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| RU2504544C2 (ru) * | 2008-10-02 | 2014-01-20 | Асахи Касеи Фарма Корпорейшн | 8-замещенные производные изохинолина и их применение |
| EP2177218A1 (en) | 2008-10-15 | 2010-04-21 | Medizinische Universität Wien | Regenerative therapy |
| JP5391372B2 (ja) * | 2009-07-08 | 2014-01-15 | 公益財団法人名古屋産業科学研究所 | 芳香族アミン化合物の製造方法 |
| CN102844305B (zh) * | 2010-03-31 | 2014-07-02 | 埃科特莱茵药品有限公司 | 抗菌异喹啉-3-基脲衍生物 |
| BR112013013790A2 (pt) | 2010-12-17 | 2016-09-13 | Hoffmann La Roche | compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
| CA2870837C (en) | 2012-05-15 | 2022-05-10 | Cancer Research Technology Limited | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| EP3027600B1 (en) | 2013-07-31 | 2022-04-06 | Novartis AG | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| US9701677B2 (en) | 2014-12-24 | 2017-07-11 | Gilead Sciences, Inc. | Fused pyrimidine compounds |
| US9624195B2 (en) | 2014-12-24 | 2017-04-18 | Gilead Sciences, Inc. | Isoquinoline compounds |
| CN117024411A (zh) | 2017-03-30 | 2023-11-10 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的异喹啉 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| EP3801500A4 (en) * | 2018-06-07 | 2022-03-02 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| WO2020023560A1 (en) * | 2018-07-24 | 2020-01-30 | F. Hoffmann-La Roche Ag | Isoquinoline compounds and uses thereof |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| CN110407777B (zh) * | 2019-08-15 | 2022-09-09 | 湖北远大富驰医药化工股份有限公司 | 一种呋虫胺的合成方法 |
| CN111574413B (zh) * | 2020-06-08 | 2022-04-05 | 杭州尚合生物医药科技有限公司 | 一种2-氨甲基吡啶与dmf-dma作为胺源的磺酰脒的制备方法 |
| CN113372341A (zh) * | 2021-07-02 | 2021-09-10 | 黄淮学院 | 三氟醋酸二氢异喹啉衍生物的合成方法及装置 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| JPH06501921A (ja) | 1990-07-31 | 1994-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 選択されたハロカーボンの触媒平衡化 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| NZ334613A (en) * | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
| JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
| JP2001514259A (ja) | 1997-08-29 | 2001-09-11 | ゼネカ・リミテッド | アミノメチルオキソオキサゾリジニルベンゼン誘導体 |
| TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| BR0107732A (pt) | 2000-01-20 | 2003-03-11 | Eisai Ltd | Método para prevenir ou tratar uma doença |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| WO2002034712A1 (fr) | 2000-10-27 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Procede de preparation de composes aromatiques substitues et produits intermediaires associes |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| CA2441492C (en) | 2001-03-23 | 2011-08-09 | Bayer Corporation | Rho-kinase inhibitors |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| AU2003281623B8 (en) * | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| US7615564B2 (en) | 2002-09-12 | 2009-11-10 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| US20040266755A1 (en) | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| WO2004113297A2 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| EP1667979A4 (en) | 2003-09-23 | 2007-04-18 | Merck & Co Inc | INHIBITORS OF POTASSIUM CHANNELS WITH ISOQUINOLINE |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| JPWO2005035516A1 (ja) | 2003-10-10 | 2006-12-21 | 小野薬品工業株式会社 | 新規縮合複素環化合物およびその用途 |
| US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| JP2005232175A (ja) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005087226A1 (en) | 2004-03-05 | 2005-09-22 | Eisai Co., Ltd. | Cadasil treatment with cholinesterase inhibitors |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| CN101228132B (zh) | 2005-07-26 | 2012-10-10 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物 |
| MX2008001053A (es) | 2005-07-26 | 2008-03-19 | Sanofi Aventis | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa. |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| JP4033221B2 (ja) | 2005-12-02 | 2008-01-16 | ダイキン工業株式会社 | 冷媒加熱装置 |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| SI2102164T1 (sl) | 2006-12-27 | 2011-03-31 | Sanofi Aventis | Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom |
| MY148902A (en) | 2006-12-27 | 2013-06-14 | Sanofi Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
-
2006
- 2006-06-13 NZ NZ565040A patent/NZ565040A/en not_active IP Right Cessation
- 2006-06-13 RS RSP-2009/0516A patent/RS51139B/sr unknown
- 2006-06-13 DE DE602006008945T patent/DE602006008945D1/de active Active
- 2006-06-13 BR BRPI0613597-8A patent/BRPI0613597A2/pt not_active IP Right Cessation
- 2006-06-13 AU AU2006264043A patent/AU2006264043B2/en not_active Ceased
- 2006-06-13 RU RU2008102968/04A patent/RU2443688C2/ru not_active IP Right Cessation
- 2006-06-13 KR KR1020077030517A patent/KR101327780B1/ko not_active IP Right Cessation
- 2006-06-13 CN CN2006800238102A patent/CN101213187B/zh not_active Expired - Fee Related
- 2006-06-13 SI SI200630484T patent/SI1899322T1/sl unknown
- 2006-06-13 JP JP2008518659A patent/JP5097701B2/ja not_active Expired - Fee Related
- 2006-06-13 CA CA2611295A patent/CA2611295C/en not_active Expired - Fee Related
- 2006-06-13 DK DK06754323T patent/DK1899322T3/da active
- 2006-06-13 WO PCT/EP2006/005648 patent/WO2007000240A1/en active Application Filing
- 2006-06-13 PL PL06754323T patent/PL1899322T3/pl unknown
- 2006-06-13 AT AT06754323T patent/ATE441641T1/de active
- 2006-06-13 EP EP06754323A patent/EP1899322B1/en active Active
- 2006-06-13 ES ES06754323T patent/ES2331853T3/es active Active
- 2006-06-13 PT PT06754323T patent/PT1899322E/pt unknown
- 2006-06-13 MX MX2008000017A patent/MX2008000017A/es active IP Right Grant
- 2006-06-26 DO DO2006000149A patent/DOP2006000149A/es unknown
- 2006-06-26 PE PE2006000735A patent/PE20070141A1/es not_active Application Discontinuation
- 2006-06-26 GT GT200600273A patent/GT200600273A/es unknown
- 2006-06-26 TW TW095122877A patent/TWI372756B/zh not_active IP Right Cessation
- 2006-06-26 AR ARP060102738A patent/AR054518A1/es unknown
- 2006-06-27 PA PA20068683501A patent/PA8683501A1/es unknown
- 2006-06-27 MY MYPI20063032A patent/MY146037A/en unknown
- 2006-06-29 UY UY29641A patent/UY29641A1/es unknown
-
2007
- 2007-11-20 ZA ZA200710001A patent/ZA200710001B/xx unknown
- 2007-12-07 MA MA30457A patent/MA29535B1/fr unknown
- 2007-12-20 US US11/961,193 patent/US8501736B2/en not_active Expired - Fee Related
- 2007-12-24 IL IL188380A patent/IL188380A/en not_active IP Right Cessation
-
2008
- 2008-12-12 HK HK08113534.8A patent/HK1122276A1/xx not_active IP Right Cessation
-
2009
- 2009-11-03 HR HR20090589T patent/HRP20090589T1/hr unknown
- 2009-11-25 CY CY20091101226T patent/CY1110108T1/el unknown
-
2011
- 2011-06-15 US US13/160,983 patent/US8722671B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090589T1 (hr) | Izokinolinski derivati kao inhibitori ro-kinaze | |
| RU2009128645A (ru) | Замещенные изохинолиновые и изохинолиноновые производные в качестве ингибиторов rho-киназы | |
| HRP20100705T1 (hr) | Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati | |
| HRP20110839T1 (hr) | Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze | |
| RU2009128693A (ru) | Замещенные производные изохинолина и изохинолинона | |
| RU2009128653A (ru) | Замещенные циклоалкиламином производные изохинолона | |
| RU2009128688A (ru) | Замещенные циклоалкиламином производные изохинолина и изохинолинона | |
| RU2008106950A (ru) | Пиперидинилзамещенные производные изохинолона как ингибиторы rho-киназы | |
| CO6190525A2 (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih | |
| RU2009128690A (ru) | Новые замещенные производные изохинолина и изохинолинона | |
| DK1856045T3 (da) | 1-eddikesyreindolderviater med PGD2-antagonisteffekt | |
| MX2009000871A (es) | Novedosos inhibidores de transcriptasa inversa de vih. | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| EA200600648A1 (ru) | Производные пурина, ингибирующие репликацию вич | |
| CA2589438C (en) | Treatment of inflammatory bowel disease | |
| MEP43308A (hr) | Derivati cikloalkilamino kisjeline i njihove farmaceutske kompozicije | |
| NO20050841L (no) | Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer | |
| AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| DE602007005811D1 (de) | 6-substituierte isochinolinderivate als rock-1-inhibitoren | |
| RU2005137032A (ru) | Применение оксазолидинон-хинолиновых гибридных антибиотиков для лечения сибирской язвы и других инфекций | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
| NO20061584L (no) | Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister | |
| MX2011007864A (es) | Isosteros para realzar la transcripcion y su uso en terapia. | |
| RU2011113967A (ru) | Новое производное простагландина i2 | |
| RU2019128534A (ru) | Химические соединения для лечения туберкулеза |